HealthEquity (NASDAQ:HQY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of HealthEquity (NASDAQ:HQY) from a hold rating to a buy rating in a research report report published on Saturday morning.

Other analysts have also issued research reports about the stock. BTIG Research raised their target price on shares of HealthEquity from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Friday. Royal Bank Of Canada boosted their target price on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Wells Fargo & Company set a $111.00 price target on shares of HealthEquity in a report on Monday, June 1st. Citizens Jmp increased their price target on HealthEquity from $110.00 to $111.00 and gave the company a “market outperform” rating in a research note on Monday, June 1st. Finally, Barrington Research reissued an “outperform” rating and set a $110.00 price objective on shares of HealthEquity in a report on Friday, May 22nd. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.93.

HealthEquity Stock Up 4.7%

Shares of NASDAQ HQY opened at $99.05 on Friday. The company has a market cap of $8.28 billion, a price-to-earnings ratio of 37.10, a PEG ratio of 1.59 and a beta of 0.21. The company has a current ratio of 3.44, a quick ratio of 3.44 and a debt-to-equity ratio of 0.46. HealthEquity has a 12 month low of $72.76 and a 12 month high of $105.96. The stock has a 50-day moving average price of $90.53 and a two-hundred day moving average price of $84.90.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Thursday, May 28th. The company reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million for the quarter, compared to the consensus estimate of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. HealthEquity’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, analysts forecast that HealthEquity will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Gayle Furgurson Wellborn sold 2,439 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the completion of the sale, the director owned 19,733 shares of the company’s stock, valued at approximately $1,775,970. This represents a 11.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total transaction of $675,000.00. Following the completion of the transaction, the executive vice president owned 91,141 shares in the company, valued at $8,202,690. This trade represents a 7.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 17,905 shares of company stock valued at $1,651,280. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

Large investors have recently bought and sold shares of the stock. Capricorn Fund Managers Ltd bought a new stake in HealthEquity in the 4th quarter valued at about $6,926,000. Oxbow Advisors LLC acquired a new stake in HealthEquity in the first quarter valued at approximately $3,147,000. Westfield Capital Management Co. LP grew its stake in HealthEquity by 13.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after acquiring an additional 235,794 shares during the period. Wasatch Advisors LP increased its holdings in shares of HealthEquity by 9.3% during the first quarter. Wasatch Advisors LP now owns 7,202,934 shares of the company’s stock valued at $601,949,000 after acquiring an additional 613,288 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd acquired a new position in shares of HealthEquity during the fourth quarter worth approximately $4,381,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.